Allan Block, MD
Neurology · Scottsdale, AZNPI 1841262110
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $253 of the $403 with a category attached, or 62.8%. 5 manufacturers reported payments, led by Biogen at 37.2% of the total. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 5 payments — averaging $80.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$150
- Zap Surgical Systems, Inc.$134
- Medline Industries LP$84
- Avanir Pharmaceuticals, Inc.$20
- Amniox Medical, Inc.$16
Across 177 payments — averaging $9979.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$796K
- E.r. Squibb & Sons, L.L.C.$317K
- Pfizer$243K
- Avanir Pharmaceuticals, Inc.$211K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$69K
- Biohaven Pharmaceutical Holding Company Ltd.$56K
- plus $76K from 6 others
What the payments were for
- Consulting fees$15037%
- Food & beverage$25363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $150 |
| Zap Surgical Systems, Inc. | 1 | $134 |
| Medline Industries LP | 1 | $84 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Amniox Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$403 in reported general payments places this provider in the 35th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 17 | $24,751 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $19,470 |
| Lacosamide | 26 | $6,421 |
| Gabapentin | 142 | $4,044 |
| Levetiracetam | 59 | $2,543 |
| Memantine Hcl | 73 | $2,205 |
| Oxcarbazepine | 37 | $2,074 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 73 | $1,756 |
| Pramipexole ErPramipexole Di-Hcl | 11 | $1,750 |
| Rasagiline Mesylate | 21 | $1,646 |
| Primidone | 35 | $1,585 |
| Sumatriptan Succinate | 17 | $1,393 |
| Pregabalin | 40 | $1,305 |
| Lamotrigine | 60 | $1,189 |
| Duloxetine Hcl | 33 | $926 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scottsdale
- Nida LaurinScottsdale$969K
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Maciej MrugalaScottsdale$97K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.